Acorda Therapeutics Inc (ACOR)

NASDAQ
10.210
-0.010(-0.10%)
After Hours
9.930
-0.280(-2.742%)
- Real-time Data
  • Volume:
    20,725
  • Day's Range:
    9.750 - 11.020
  • 52 wk Range:
    5.222 - 24.800

ACOR Overview

Prev. Close
10.22
Day's Range
9.75-11.02
Revenue
118.29M
Open
9.93
52 wk Range
5.222-24.8
EPS
-51.8
Volume
20,725
Market Cap
12.42M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
44,340
P/E Ratio
-
Beta
1.37
1-Year Change
64.94%
Shares Outstanding
1,216,884
Next Earnings Date
02 Aug 2023
What is your sentiment on Acorda?
or
Market is currently closed. Voting is open during market hours.

Acorda Therapeutics Inc Company Profile

Acorda Therapeutics Inc Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellSellStrong SellStrong Sell
Technical IndicatorsNeutralSellStrong BuyStrong SellStrong Sell
SummaryNeutralStrong SellNeutralStrong SellStrong Sell
  • What’s the news??
    0